ACAndrea Costantini

Andrea Costantini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrea Costantini has a total of 670 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation

    by Cristina Mussini, Andrea Giacomelli, Eugenia Quiros-Roldan, Valentina Mazzotta, Antonio Di Biagio, Andrea De Vito, Andrea Costantini, Gabriella D'ETtorre, Andrea Giacometti, Alessandra Vergori, et al.


  • Open Access

    SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio

    by Alessandra Vergori, Alessandro Tavelli, Giulia Matusali, Anna Maria Azzini, Matteo Augello, Valentina Mazzotta, Giovanni Francesco Pellicanò, Andrea Costantini, Antonio Cascio, Andrea De Vito, et al.

    Background: Our aim was to estimate the rates of not achieving a robust/above-average humoral response to the COVID-19 mRNA vaccine in people living with HIV (PLWH) who received ≥2 doses and to investigate the role of the CD4 and CD4/CD8 ratio in predicting the humoral response. Methods: We evaluated the humoral anti-SARS-CoV-2 response 1-month after the second and third doses of COVID-19 mRNA vaccine as a proportion of not achieving a robust/above-average response using two criteria: (i) a humoral threshold identified as a correlate of protection against SARS-CoV-2 ( 200 cells/mm3 and a ratio > 0.6. Conclusions: A robust humoral response after a booster dose has not been reached by 50% of PLWH with CD4 < 200 cells mm3. In the absence of a validated correlate of protections in the Omicron era, the CD4 count remains the most solid marker to guide vaccination campaigns in PLWH.


  • Open Access

    Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

    by Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, et al.

  • 1307 COMPLEMENTARY PNEUMATIC DILATIONS ARE AN EFFECTIVE AND SAFE OPTION WHEN LAPAROSCOPIC MYOTOMY FAILS TO TREAT ESOPHAGEAL ACHALASIA.

    by Andrea Costantini, Renato Salvador, Luca Provenzano, Giovanni Capovilla, Loredana Nicoletti, Francesca Forattini, Arianna Vittori, Giulia Nezi, Michele Valmasoni, Mario Costantini

  • P1 Data-Linkage Between Administrative and Pathological Anatomy Databases for the Identification of Lung Cancer Patients Eligible to Innovative Therapies

    by L Degli Esposti, D Sangiorgi, M Andretta, M Bacca, A Barbieri, F Bartolini, A Cavaliere, A Chinellato, A Ciaccia, Cillo, et al.

  • Predictive comorbidities of hospital admission in 1,571 SARS- CoV-2 positive patients: analysis of administrative data from an Italian Local Health Autority.

    by F Cedrone, F Santoleri, G Di Martino, F Carfagnini, A Romagnoli, A Catalini, L Del Duca, V Fortunato, A Costantini

    Globally, age and some comorbidities have been associ-ated with the risk of more severe outcomes of COVID-19. The purpose of this research is to calculate the hospitalization rate of SARS-CoV-2 positive patients in an Italian Local health Authority (LHA) and to examine whether medical comorbidities encoded through pharmaceutical administrative data are predictors of hospital admission in patients with a positive SARS-CoV-2 naso-pharyngeal swab. This retrospective observational study was conducted in a LHA of Pescara. Comorbidities were coded through the consumption of drugs, using the WHO's Anatomical Therapeutic Chemical (ATC) classification System. The admission was ascertained by checking the hospital discharge records where generated. During the study period, 1571 patients were tested positive for SARS-CoV-2 oro-and-nasopharyngeal swab. Multivariable logistic analisys showed as predictors of admission an age ≥65 in the total sample (aOR 10.91; 95%CI 6.86-17.36) as well as in the male (aOR 12.64;95%CI 6.42-24.87) and female. (aOR 9.27; 95%CI 4.87-17.66) in SARS-CoV-2 positive patients. Comorbidities assiociated with admission were (GERD) in overall (AdjOR 1.58; 95% CI 1.06-2.34) and male (AdjOR 2.30; 95%CI 1.12-4.72) samples and anticoagulants drugs use in male (AdjOR 3.90; 95% 1.11-13.65) sample, the presence of congestive heart failure (CHF) in female (AdjOR 0.47;95%CI 0.27-0.83) sample results as protective factor. In conclusion, increasing age, male gender and PPI use are positively associated while female gender and CHF-related drug use are negatively associated with hospitalization in SARS-CoV-2 positive patients.

  • Open Access

    5PSQ-214 ‘Unit dose’: clinical risk management of COVID-19 patients treated with hydroxychloroquine

    by S Corridoni, P Sorice, L Auriemma, S Pizzica, C Cinalli, G Di Florio, F Gasbarri, L Armillei, A Romagnoli, S Massacese, et al.

    Background and importance The use of unit dose (UD) has been proved to be a critical tool in supporting the phases of prescription, preparation and administration of therapies, and most importantly in the management of the COVID-19 emergency. All drugs managed in the UD are screened and validated by the pharmacist; during this stage, if any prescription presents a potential risk of adverse events for a patient, the pharmacist is required to insert notes requesting modification of the prescription. These notes provide information about the risk of potential errors such as therapy duration, dosage, administration frequency, interactions, therapeutic indications, dilution, type of formulation and double prescriptions. Aim and objectives The aim of this work was to demonstrate the key role that pharmacists play in patient safety and clinical risk management, particularly in the prescription of hydroxychloroquine (HCQ) for COVID-19 patients. Material and methods We analysed therapies from all patients managed with UD in the period 1 March 2020 to 31 July 2020, and reviewed the notes entered by the pharmacists. These notes were further divided based on the potential risk of event/error, latent/active and high and low risk (HR, LW), where high risk refers to potentially harmful events for the patient. Results During the observed period, hospitalised patients receiving the UD regimen were 4649 patients, 413 resulting from COVID-19, including 231 men and 182 women, with a median age of 70 (20–99) years and average number of hospitalisation days of 19 (SD±17). In 334 (81%) prescriptions for these patients, one or more notes were reported from the pharmacist, including 283 HR and 51 LR. The total number of notes entered were 445, with 322 (72%) related to HCQ interactions as follows: (1) 67% medicines that prolong the QT interval which can induce heart rhythm disorders (class IA and III antiarrhythmics, tricyclic antidepressants, antipsychotics, macrolides and quinolones); (2) 3% digoxin; (3) 20% antidiabetics; and (4) 10% antiepileptics. Conclusion and relevance This study showed that in 72% of notes reported in advance by the pharmacist in the prescription, there was a HR of potential adverse events resulting from the interaction with HCQ. This led to interruption in the use of this drug, as subsequently confirmed by the decision of the EMA (29 May 2020) to recommend its use only in clinical trials. Conflict of interest No conflict of interest


  • Open Access

    Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy

    by Lavinia Fabeni, Maria Mercedes Santoro, Patrizia Lorenzini, Stefano Rusconi, Nicola Gianotti, Andrea Costantini, Loredana Sarmati, Andrea Antinori, Francesca Ceccherini-Silberstein, Antonella D’arminio Monforte, et al.

    We aimed at evaluating the characteristics of HIV-1 molecular transmission clusters (MTCs) among natives and migrants living in Italy, diagnosed between 1998 and 2018. Phylogenetic analyses were performed on HIV-1 polymerase (pol) sequences to characterise subtypes and identify MTCs, divided into small (SMTCs, 2–3 sequences), medium (MMTCs, 4–9 sequences) and large (LMTCs, ≥10 sequences). Among 3499 drug-naïve individuals enrolled in the Italian Cohort Naive Antiretroviral (ICONA) cohort (2804 natives; 695 migrants), 726 (20.8%; 644 natives, 82 migrants) were involved in 228 MTCs (6 LMTCs, 36 MMTCs, 186 SMTCs). Migrants contributed 14.4% to SMTCs, 7.6% to MMTCs and 7.1% to LMTCs, respectively. HIV-1 non-B subtypes were found in 51 MTCs; noteworthy was that non-B infections involved in MTCs were more commonly found in natives (n = 47) than in migrants (n = 4). Factors such as Italian origin, being men who have sex with men (MSM), younger age, more recent diagnosis and a higher CD4 count were significantly associated with MTCs. Our findings show that HIV-1 clustering transmission among newly diagnosed individuals living in Italy is prevalently driven by natives, mainly MSM, with a more recent diagnosis and frequently infected with HIV-1 non-B subtypes. These results can contribute to monitoring of the HIV epidemic and guiding the public health response to prevent new HIV infections.


  • Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis

    by Michele Maria Luchetti, Francesco Ciccia, Chiara Avellini, Devis Benfaremo, Aroldo Rizzo, Tatiana Spadoni, Silvia Svegliati, Daniela Marzioni, Alfredo Santinelli, Andrea Costantini, et al.

    Objectives: Gut microbiota has been widely reported to be involved in systemic inflammation through microbial translocation and T cell activation in several diseases. In this work we aimed to investigate bacterial infiltration and epithelial impairment in the gut of patients with IBD-associated SpA (SpA-IBD), as well as the relationship of microbial translocation with immune system activation and their putative role in the pathogenesis of joint inflammation in IBD patients. Methods: Tight-junction proteins (TJPs) occludin and claudin-1/-4 and bacteria were assessed by real-time PCR analysis and immunohistochemical staining of the ileum. Intestinal fatty acid binding protein (I-FABP), lipopolysaccharides (LPS), soluble CD14 (sCD14), sclerostin and anti-sclerostin antibodies (anti-sclerostin-IgG) were assayed with ELISAs and peripheral mononuclear blood cells with flow cytometry. LPS and sCD14 were used in vitro to stimulate a human osteoblast cell line. Results: Compared with IBD, ileal samples from SpA-IBD patients showed bacterial infiltration, epithelial damage and downregulation of TJPs. In sera, they showed higher serum levels of I-FABP, LPS, sCD14 (the latter correlating with sclerostin and anti-sclerostin-IgG) and higher CD80+/CD163+ and lower CD14+ mononuclear cells. In vitro experiments demonstrated that only the LPS and sCD14 synergic action downregulates sclerostin expression in osteoblast cells. Conclusion: SpA-IBD patients are characterized by gut epithelium impairment with consequent translocation of microbial products into the bloodstream, immune system activation and an increase of specific soluble biomarkers. These findings suggest that gut dysbiosis could be involved in the pathogenesis of SpA-IBD and it could hopefully prompt the use of these biomarkers in the follow-up and management of IBD patients.


  • Open Access

    Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway

    by Elena Marinelli Busilacchi, Andrea Costantini, Giorgia Mancini, Giovanni Tossetta, Jacopo Olivieri, Antonella Poloni, Nadia Viola, Luca Butini, Anna Campanati, Gaia Goteri, et al.